ReviewFrontiers in cell and developmental biology2026
TRIM family proteins: dual roles in tumor immunity.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tripartite motif (TRIM) proteins represent one of the largest subfamilies of E3 ubiquitin ligases and exert complex yet critical dual roles in tumor immunology by orchestrating protein ubiquitination. This review systematically delineates the multifaceted regulatory roles of TRIM proteins in tumor immunity, with a focus on their dual functions within the tumor immune microenvironment, particularly regarding immune checkpoints and tumor-infiltrating immune cells. Notably, the same TRIM protein may exert opposing immunomodulatory effects in different tumor types or microenvironmental contexts, underscoring the critical influence of context on their functions. This article aims to synthesize current advances in understanding the dual roles of the TRIM family in tumor immunity and to discuss their potential and challenges as novel targets for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.